期刊文献+

奥曲肽对小鼠结肠癌肝转移化疗的影响 被引量:1

Influence of 5-fluorouracilum combined with octreotide on chemotherapy of hepatic metastases of colonic carcinoma
下载PDF
导出
摘要 目的:探讨生长抑素衍生物奥曲肽(又名善得定)对动物结肠癌肝转移瘤5-氟尿嘧啶(5-Fu)化学治疗的影响。方法:采用流式细胞术等方法观察奥曲肽对小鼠CT26结肠癌肝转移瘤5-Fu 化学治疗的影响。结果:与对照组比较,奥曲肽加5-Fu联合治疗后,肿瘤细胞动力学参数(细胞增殖指数和S期分数)的变化比两者单一用药更为显著,肝脏表面肿瘤数目也更为减少,而小鼠的生存期却相对延长。结论:奥曲肽对5-Fu 的抗肿瘤作用有一定的增强效应,初步推测这种增强作用的机制与两种制剂对肿瘤细胞周期特异性抑制有关。 Objective: To study the chemotherapy effect of 5 fluorouracilum (5 Fu) combined with octreotide on hepatic metastases of colonic carcinoma. Methods: The influence of chemotherapy by 5 Fu combined with somatostatin analogue octreotide on cytokinetics of hepatic metastases from colonic adenocarcinoma were investigated by flow cytometry. Results: The changes of tumor cytokinetics parameters (e.g. proliferative index, S phase fraction and so on), the incidence of hepatic metastases and the survival time of mice in combined treatment were more obvious than that of single treatment. Conclusion: Octreotide is beneficial to chemotherapy of 5 Fu. The mechanism of anti tumor effect by combination of both may be associated with the inhibitory effect of tumor cell cycle specifically.
出处 《第二军医大学学报》 CAS CSCD 北大核心 1999年第11期892-894,共3页 Academic Journal of Second Military Medical University
关键词 5-氟尿嘧啶 结肠肿瘤 奥曲肽 肝转移 fluorouracilum colonic neoplasms octreotide
  • 相关文献

参考文献6

  • 1何友兼 管忠震 等.FAM方案在胃癌治疗上的应用[J].癌症,1989,8(2):142-144.
  • 2刘瑞,唐岩,曹贵松,王元和.生长抑素对肝脏转移性结肠腺癌的抑制作用[J].中华实验外科杂志,1997,14(3):130-131. 被引量:7
  • 3左中孔 郎统伦 等.大剂量丝裂霉素联合优福定治疗晚期胃癌35例临床探讨[J].癌症,1989,8(6):448-488.
  • 4张祥福 郑知文 等.5-氟脲嘧啶、阿霉素和丝裂霉素(FAM)联合治疗晚期胃癌31例报告[J].肿瘤防治研究,1988,15(2):111-111.
  • 5刘瑞,中国肿瘤临床,1996年,23卷,增刊,20页
  • 6许立功,孙曾一.胃癌化疗的进展及辅助性化疗[J].普外临床,1990,5(5):307-310. 被引量:7

共引文献13

同被引文献9

  • 1Frizelle FA. Octreotide inhibits the growth and development of three types of experimental liver metastasis[J]. BR J Surg,1995, 82: 1577.
  • 2Imam H, Eriksson B, Lumkinius A, et al. Induction of apoptosis in neuroendocrine tumours osf thd digestive system during treament woth somatostatin analogs[J]. Acta Oncol, 1997,36 : 607.
  • 3Nakaizumi A, Uehara H, Bara M, et al. Inhibition by somatostatin of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats[J ]. Carcinogenesis, 1993,14: 2601.
  • 4Schinded D T, Grosfeld J L. Hepatic resection enhanes growth of residual intrahepatic and subcutaneous hepatoma which is inhibited by octreotide[J]. J Pediatr Surg, 1997,32 : 995.
  • 5Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study[J]. Gut, 1998, 42: 442.
  • 6Samonakis D N, Moschandreas J, Arnaoutis T, et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues[J]. Oncol Rep, 2002, 9(4): 903.
  • 7Gyr K E, Meier R. Pharmacodymmic effects of sandostatin in the gastrointestinal tract[J]. Digestion, 1993, 54(Suppl 1):14.
  • 8Van Eijek C H J, Slooter G D, Hofland L J, et al. Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide[J]. Br J Surg, 1994, 81(7) : 1333.
  • 9Weckbecker G, Raulf F, Tolcsvai L, et al. Potentiation of the anti - proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo[J]. Digestion, 1996, (Suppl 1):22.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部